无水乙醇明胶海绵混合物栓塞治疗肝癌合并中重度肝动脉门静脉分流的疗效分析
发布时间：2018-08-26 08:30
【摘要】：目的探讨采用无水乙醇明胶海绵混合物(ESG)联合化疗药物和/或碘化油,对合并中重度肝动脉门静脉分流(APS)的肝癌(HCC)患者行末梢性化疗栓塞的安全性和有效性。方法回顾性分析2008年6月至2015年12月使用ESG栓塞治疗106例HCC合并中重度APS患者的临床资料,对于手术前后APS改善情况、手术相关并发症、肿瘤反应、生存期和预后因素等进行统计学分析。结果 106例HCC合并中重度APS的患者中位生存期为278 d,6、12、18个月累积生存率分别为70.8%、36.1%、16.0%。单因素分析结果显示:性别、总胆红素水平、最大肿瘤直径、既往治疗、治疗有无应答以及APS改善与患者预后相关。多因素分析结果显示:治疗有应答、APS改善是独立保护因素,而女性、最大肿瘤直径≥5 cm为独立危险因素。结论采用ESG栓塞治疗合并中重度APS的HCC患者安全、有效,治疗有应答、APS改善患者预后较好,而女性、最大肿瘤直径≥5 cm为患者预后危险因素。
[Abstract]:Objective to investigate the safety and efficacy of ethanol gelfoam mixture (ESG) combined with chemotherapeutic drugs and / or lipiodol in the treatment of hepatocellular carcinoma (HCC) with moderate and severe hepatic artery and portal vein shunt (APS). Methods from June 2008 to December 2015, the clinical data of 106 HCC patients with moderate and severe APS treated by ESG embolization were retrospectively analyzed. The improvement of APS before and after operation, surgical complications and tumor reaction were analyzed retrospectively. Survival time and prognostic factors were analyzed statistically. Results the median survival time of 106 patients with HCC combined with moderate and severe APS was 278d or 612.The cumulative survival rate of 18 months was 70.8 / 36.1 / 16.0, respectively. Univariate analysis showed that sex, total bilirubin level, maximum tumor diameter, past treatment, response to treatment and improvement of APS were associated with prognosis. The results of multivariate analysis showed that the improvement of response to APS was an independent protective factor, while in women, the maximum tumor diameter 鈮，
本文编号：2204298
[Abstract]:Objective to investigate the safety and efficacy of ethanol gelfoam mixture (ESG) combined with chemotherapeutic drugs and / or lipiodol in the treatment of hepatocellular carcinoma (HCC) with moderate and severe hepatic artery and portal vein shunt (APS). Methods from June 2008 to December 2015, the clinical data of 106 HCC patients with moderate and severe APS treated by ESG embolization were retrospectively analyzed. The improvement of APS before and after operation, surgical complications and tumor reaction were analyzed retrospectively. Survival time and prognostic factors were analyzed statistically. Results the median survival time of 106 patients with HCC combined with moderate and severe APS was 278d or 612.The cumulative survival rate of 18 months was 70.8 / 36.1 / 16.0, respectively. Univariate analysis showed that sex, total bilirubin level, maximum tumor diameter, past treatment, response to treatment and improvement of APS were associated with prognosis. The results of multivariate analysis showed that the improvement of response to APS was an independent protective factor, while in women, the maximum tumor diameter 鈮，
本文编号：2204298
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2204298.html
